MA41411B1 - Compositions dispersibles - Google Patents

Compositions dispersibles

Info

Publication number
MA41411B1
MA41411B1 MA41411A MA41411A MA41411B1 MA 41411 B1 MA41411 B1 MA 41411B1 MA 41411 A MA41411 A MA 41411A MA 41411 A MA41411 A MA 41411A MA 41411 B1 MA41411 B1 MA 41411B1
Authority
MA
Morocco
Prior art keywords
compositions
dispersible compositions
useful
dispersible
pediatric
Prior art date
Application number
MA41411A
Other languages
English (en)
Other versions
MA41411A (fr
Inventor
Manish Gupta
Shripad Marathe
Kaustubh Tambwekar
Shreedevi Nair
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA41411A publication Critical patent/MA41411A/fr
Publication of MA41411B1 publication Critical patent/MA41411B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions dispersibles comprenant du fumarate de bédaquiline comme principe actif. Ces compositions s'avèrent utiles dans le traitement de la tuberculose et leurs propriétés inhérentes de dispersibilité les rend utiles notamment auprès de la population pédiatrique ou gériatrique.
MA41411A 2015-01-27 2016-01-26 Compositions dispersibles MA41411B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN264MU2015 2015-01-27
PCT/EP2016/051545 WO2016120258A1 (fr) 2015-01-27 2016-01-26 Compositions dispersibles

Publications (2)

Publication Number Publication Date
MA41411A MA41411A (fr) 2017-12-05
MA41411B1 true MA41411B1 (fr) 2023-07-31

Family

ID=55229712

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41411A MA41411B1 (fr) 2015-01-27 2016-01-26 Compositions dispersibles

Country Status (29)

Country Link
US (2) US20180000810A1 (fr)
EP (1) EP3250182B1 (fr)
JP (3) JP7291458B2 (fr)
KR (1) KR102631986B1 (fr)
CN (2) CN114129526A (fr)
AU (2) AU2016212116B2 (fr)
CA (1) CA2973301A1 (fr)
CY (1) CY1126107T1 (fr)
DK (1) DK3250182T3 (fr)
EA (1) EA201791701A1 (fr)
ES (1) ES2948805T3 (fr)
FI (1) FI3250182T3 (fr)
HK (1) HK1243644A1 (fr)
HR (1) HRP20230616T1 (fr)
HU (1) HUE062481T2 (fr)
IL (2) IL310920A (fr)
LT (1) LT3250182T (fr)
MA (1) MA41411B1 (fr)
MD (1) MD3250182T2 (fr)
MX (1) MX2017009681A (fr)
PE (1) PE20171319A1 (fr)
PH (1) PH12017501331A1 (fr)
PL (1) PL3250182T3 (fr)
PT (1) PT3250182T (fr)
RS (1) RS64308B1 (fr)
SG (1) SG11201705944TA (fr)
SI (1) SI3250182T1 (fr)
UA (1) UA126891C2 (fr)
WO (1) WO2016120258A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
WO2019012100A1 (fr) * 2017-07-14 2019-01-17 Janssen Pharmaceutica Nv Formulations à action prolongée
WO2019193609A1 (fr) * 2018-04-05 2019-10-10 Cipla Limited Formulations pharmaceutiques
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
JP2022516671A (ja) * 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2021257461A1 (fr) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Composition antibactérienne polythérapeutique et méthode de thérapie antibactérienne
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
KR102478006B1 (ko) 2020-12-03 2022-12-15 정승찬 자동차 긴급 제동장치
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL222801B1 (pl) 2002-07-25 2016-09-30 Janssen Pharmaceutica Nv Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je
EP1753427B1 (fr) 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Utilisation de derives substitues de quinoline dans le traitement de maladies mycobacteriennes resistantes aux medicaments
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
JP5410749B2 (ja) * 2005-05-25 2014-02-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （アルファｓ，ベータｒ）−６−ブロモ−アルファ−［２−（ジメチルアミノ）エチル］−２−メトキシ−アルファ−１−ナフタレニル−ベータ−フェニル−３−キノリンエタノールの製造方法
CA2528849C (fr) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Derives de quinoleine utilises comme agents antibacteriens
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
EP2271320A4 (fr) * 2008-04-02 2011-05-18 Reddys Lab Ltd Dr Formulations pharmaceutiques de raloxifène
CA2735229C (fr) * 2008-09-03 2014-01-28 Pfizer Inc. Therapie combinee pour la tuberculose
US20120207838A1 (en) * 2011-02-10 2012-08-16 Perricone Nicholas V Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
WO2013153162A1 (fr) * 2012-04-11 2013-10-17 Sandoz Ag Polymorphe de chlorhydrate de rilpivirine
US20140075692A1 (en) * 2012-09-18 2014-03-20 Unger Marketing International, Llc. Multiuse cleaning tool handle
JP2015537013A (ja) * 2012-11-19 2015-12-24 アサンタ・アー／エス 速崩性錠剤

Also Published As

Publication number Publication date
LT3250182T (lt) 2023-07-10
WO2016120258A1 (fr) 2016-08-04
FI3250182T3 (fi) 2023-06-28
EA201791701A1 (ru) 2017-11-30
IL310920A (en) 2024-04-01
PL3250182T3 (pl) 2023-07-31
RS64308B1 (sr) 2023-07-31
MX2017009681A (es) 2017-10-18
JP7291458B2 (ja) 2023-06-15
SI3250182T1 (sl) 2023-08-31
BR112017015784A2 (pt) 2018-03-27
IL253626B1 (en) 2024-04-01
MD3250182T2 (ro) 2023-09-30
HUE062481T2 (hu) 2023-11-28
HRP20230616T1 (hr) 2023-09-29
SG11201705944TA (en) 2017-08-30
EP3250182A1 (fr) 2017-12-06
PE20171319A1 (es) 2017-09-07
AU2021204135B2 (en) 2023-10-05
CN107205945A (zh) 2017-09-26
IL253626A0 (en) 2017-09-28
JP2018502928A (ja) 2018-02-01
JP2022176982A (ja) 2022-11-30
US20180000810A1 (en) 2018-01-04
AU2021204135A1 (en) 2021-07-15
AU2016212116B2 (en) 2021-07-15
ES2948805T3 (es) 2023-09-19
MA41411A (fr) 2017-12-05
HK1243644A1 (zh) 2018-07-20
CN114129526A (zh) 2022-03-04
CA2973301A1 (fr) 2016-08-04
DK3250182T3 (da) 2023-06-26
CY1126107T1 (el) 2023-11-15
AU2016212116A1 (en) 2017-07-27
EP3250182B1 (fr) 2023-04-26
KR20170106447A (ko) 2017-09-20
UA126891C2 (uk) 2023-02-22
JP2021098706A (ja) 2021-07-01
US20220331307A1 (en) 2022-10-20
KR102631986B1 (ko) 2024-01-30
PH12017501331A1 (en) 2017-12-11
PT3250182T (pt) 2023-07-07

Similar Documents

Publication Publication Date Title
MA41411B1 (fr) Compositions dispersibles
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
MA41013A (fr) Compositions comprenant des souches bactériennes
MA53937B1 (fr) Compositions comprenant des souches bactériennes
WO2018115097A9 (fr) Composition ophtalmologique pour le traitement du syndrome de l'oeil sec
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
MX2019008544A (es) Nueva formulacion estable para anticuerpos anti-fxia.
WO2016057413A3 (fr) Inhibiteurs de lysine gingipaïne
EA202092225A1 (ru) Соединения и их применение
MA35457B1 (fr) Nouvelles formulations de pyriméthanil et leur utilisations dans le traitement des cultures
EP4269549A3 (fr) Composition de nettoyage de la peau
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
EP4272832A3 (fr) Composés antimicrobiens, compositions et leurs utilisations
MA46563B1 (fr) Compositions dispersibles
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2014011218A (es) Uso de agentes tensoactivos anfotericos para la prevencion y tratamiento de biopeliculas vaginales patogenas en infecciones vaginales.
MA40805A (fr) Compositions pharmaceutiques à action prolongée contre l'hépatite c